173 related articles for article (PubMed ID: 37942566)
41. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
42. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.
Hoylman E; Brown A; Perissinotti AJ; Marini BL; Pianko M; Ye JC; Campagnaro E; Nachar VR
Leuk Lymphoma; 2020 Mar; 61(3):691-698. PubMed ID: 31739729
[TBL] [Abstract][Full Text] [Related]
43. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Jia YJ; Liu H; Wang LR; Wang T; Feng R; Chen YJ; Wang M; Guo HX; Wen L; Duan WB; Yang YZ; Wang FR; Chen YY; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):347-352. PubMed ID: 32370462
[No Abstract] [Full Text] [Related]
44. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
[TBL] [Abstract][Full Text] [Related]
45. Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.
Arnall JR; Maples KT; Harvey RD; Moore DC
Ann Pharmacother; 2022 Aug; 56(8):927-940. PubMed ID: 34963325
[TBL] [Abstract][Full Text] [Related]
46. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
Stakiw J; Kodad S; LeBlanc R; Sebag M; Hay AE; Kukreti V; Côté J; Camacho F; Fu M; Gul E; Reece D
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):484-490. PubMed ID: 37127473
[TBL] [Abstract][Full Text] [Related]
47. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
48. Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel.
Girmenia C; Cavo M; Corso A; Di Raimondo F; Musto P; Offidani M; Petrucci MT; Rosato A; Barosi G
Crit Rev Oncol Hematol; 2022 Apr; 172():103623. PubMed ID: 35151867
[TBL] [Abstract][Full Text] [Related]
49. Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers.
Cook G; Ashcroft J; Fernandez M; Henshaw S; Khalaf Z; Pratt G; Tailor A; Rabin N
Front Oncol; 2023; 13():1063144. PubMed ID: 36910662
[TBL] [Abstract][Full Text] [Related]
50. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.
Abdallah AO; Mahmoudjafari Z; Ahmed N; Cui W; Shune L; McGuirk J; Mohan M; Mohyuddin GR; Afrough A; Alkharabsheh O; Atrash S
Eur J Haematol; 2023 Jun; 110(6):626-632. PubMed ID: 36752328
[TBL] [Abstract][Full Text] [Related]
51. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
52. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.
Byun JM; Yoon SS; Koh Y; Kim I; Jo J; Park H; Lee JO; Lee J
Anticancer Res; 2019 Sep; 39(9):5165-5170. PubMed ID: 31519629
[TBL] [Abstract][Full Text] [Related]
53. Daratumumab for the treatment of multiple myeloma.
Goldsmith SR; Foley N; Schroeder MA
Drugs Today (Barc); 2021 Oct; 57(10):591-605. PubMed ID: 34713868
[TBL] [Abstract][Full Text] [Related]
54. Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.
Beksac M; Aydin Y; Goker H; Turgut M; Besisik SK; Cagirgan S; Tuglular T; Vural F; Yagci M; Alacacioglu I; Aytan P; Goksoy HS; Gulbas Z; Gunes AK; Gurkan E; Hacioglu SK; Karti SS; Kaynar L; Ozdogu H; Paydas S; Solmaz S; Sonmez M; Tekgunduz E; Yildirim R; Ilhan O
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e474-e484. PubMed ID: 32482539
[TBL] [Abstract][Full Text] [Related]
55. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
[TBL] [Abstract][Full Text] [Related]
56. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Goldschmidt H; Moreau P; Ludwig H; Niesvizky R; Chng WJ; Joshua D; Weisel K; Spencer A; Orlowski RZ; Feng S; Iskander KS; Dimopoulos MA
Leuk Lymphoma; 2018 Jun; 59(6):1364-1374. PubMed ID: 28937327
[TBL] [Abstract][Full Text] [Related]
57. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
58. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
59. Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).
Chari A; Romanus D; DasMahapatra P; Hoole M; Lowe M; Curran C; Campbell S; Bell JA
Oncologist; 2019 Nov; 24(11):1479-1487. PubMed ID: 31371520
[TBL] [Abstract][Full Text] [Related]
60. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
